

Original Article

NecroX-5 protects mitochondrial oxidative phosphorylation capacity and preserves PGC1 α expression levels during hypoxia/reoxygenation injury

Vu Thi Thu^{1,2,#}, Hyoung Kyu Kim^{1,#}, Le Thanh Long¹, Bayalagmaa Nyamaa¹, In-Sung Song¹, To Thanh Thuy², Nguyen Quang Huy², Jubert Marquez¹, Soon Ha Kim³, Nari Kim¹, Kyung Soo Ko¹, Byoung Doo Rhee¹, and Jin Han^{1,*}

¹National Research Laboratory for Mitochondrial Signaling, Department of Physiology, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Busan 47392, Korea, ²Faculty of Biology, VNU University of Science, Hanoi 120036, Vietnam, ³Product Strategy and Development, LG Life Sciences Ltd, Seoul 03184, Korea

ARTICLE INFO

Received December 2, 2015
Revised January 11, 2016
Accepted January 13, 2016

*Correspondence

Jin Han
E-mail: phyhanj@inje.ac.kr

Key Words

Hypoxia
Mitochondria
NecroX
Oxidative phosphorylation
PGC1 α

[#]These authors contributed equally to this study.

ABSTRACT Although the antioxidant and cardioprotective effects of NecroX-5 on various *in vitro* and *in vivo* models have been demonstrated, the action of this compound on the mitochondrial oxidative phosphorylation system remains unclear. Here we verify the role of NecroX-5 in protecting mitochondrial oxidative phosphorylation capacity during hypoxia-reoxygenation (HR). NecroX-5 treatment (10 μ M) and non-treatment were employed on isolated rat hearts during hypoxia/reoxygenation treatment using an *ex vivo* Langendorff system. Proteomic analysis was performed using liquid chromatography-mass spectrometry (LC-MS) and non-labeling peptide count protein quantification. Real-time PCR, western blot, citrate synthases and mitochondrial complex activity assays were then performed to assess heart function. Treatment with NecroX-5 during hypoxia significantly preserved electron transport chain proteins involved in oxidative phosphorylation and metabolic functions. NecroX-5 also improved mitochondrial complex I, II, and V function. Additionally, markedly higher peroxisome proliferator-activated receptor-gamma coactivator-1 α (PGC1 α) expression levels were observed in NecroX-5-treated rat hearts. These novel results provide convincing evidence for the role of NecroX-5 in protecting mitochondrial oxidative phosphorylation capacity and in preserving PGC1 α during cardiac HR injuries.

INTRODUCTION

Myocardial ischemia (MI) results from reduced blood flow to the heart. MI may damage the heart muscle and in severe cases may cause heart failure and sudden death. Reperfusion-blood resupply to the cardiac muscle may reduce myocardial damage and therefore is the first choice treatment for patients suffering from MI. Nevertheless, reperfusion itself results in widespread oxidative modifications to lipids and proteins and causes mitochondrial damage, which can eventually cause

further myocardial injury [1]. Potential mediators of ischemia-reperfusion (IR) injury play roles in oxidative stress, intracellular and mitochondrial Ca²⁺ overload, and the accumulation of inflammatory cells in the infarcted myocardial tissue [1-3]. A recent trend in the application of reperfusion therapy is targeted drug delivery to the affected site [4,5].

Emerging evidence has demonstrated that preservation of mitochondrial function is important for limiting myocardial damage in ischemic heart diseases [6-9]. Activation of mitochondrial biogenesis, a complex process involving the coordi-



This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright © Korean J Physiol Pharmacol, pISSN 1226-4512, eISSN 2093-3827

Author contributions: V.T.T. and H.K.K. designed experiments and performed animal experiments. L.T.L. performed langendorff heart experiments. B.N., I.S. S. and J.M. performed western blot analysis. T.T.T. and N.Q.H. contributed to proteome analysis. S.H.K. and N.K. contributed to chemical preparation. K.S.K. and B.D.R. contributed to mitochondria complex assays. J.H. supervised and coordinated the study. V.T.T. and H.K.K. wrote the manuscript.

nated expression of mitochondrial and nuclear genes, is a nature-adaptive reaction designed to restore mitochondrial function under ischemic conditions [10]. Alteration of mitochondrial biogenesis is associated with changes in mitochondrial bioenergetics, including alterations in the oxidative phosphorylation (OXPHOS) system, mitochondrial membrane potential ($\Delta\Psi_m$), mitochondrial oxygen consumption, and ATP production. Additionally, almost every functional aspect of OXPHOS strongly influences mitochondrial respiration [6]. Transcription factors regulating the expression of major OXPHOS proteins play important roles in modifying cardiac energy metabolism [11]. One of the most well-known of these transcription factors is peroxisome proliferator-activated receptor- γ coactivator-1 α (PGC1 α) [12]. Studies have demonstrated decreased PGC1 α expression levels during myocardial infarction [13,14], and treatment with metformin [14] or losartan [13] can reduce IR injuries with significant increases in PGC1 α expression levels and enhancement of left ventricular function.

Recently, we developed NecroX compounds, cell-permeable necrosis inhibitors with antioxidant activity that localize mainly in the mitochondria [15]. One of these NecroX derivatives, NecroX-5 (C₂₅H₃₁N₃O₃S; molecular weight 453.61 kDa), when administered during hypoxia, strongly protects rat heart mitochondria against reperfusion injury by reducing mitochondrial oxidative stress, preserving the $\Delta\Psi_m$, improving mitochondrial oxygen consumption, and attenuating mitochondrial Ca²⁺ accumulation by inhibiting the mitochondrial calcium uniporter [16]. NecroX-5 also suppresses sodium nitroprusside-induced cardiac cell death by inhibiting c-Jun N-terminal kinases and caspase-3 activation [17]. Additionally, NecroX-7, a NecroX series derivative functionally and chemically similar to NecroX-5, reduces hepatic necrosis and inflammation in IR injury [18]. These results together suggest that NecroX-5 and other NecroX compounds may serve as drugs that can be used concurrently with reperfusion treatment to improve the overall efficiency of the treatment by reducing potentially harmful effects of reperfusion. Here, we further validate the role of NecroX-5 in preventing mitochondrial dysfunction during IR injury by preserving mitochondrial oxidative phosphorylation capacity.

METHODS

Ethics statement

This investigation conformed to the rules and protocols of the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (NIH Publication No. 85-23, revised 1996). All experimental procedures were reviewed and approved by the Institutional Review Board of Animals at Inje University College of Medicine. Procedures were performed according to the Institutional Review Board.

Isolation of hearts

Eight-week-old male Sprague–Dawley rats (200–250 g) were deeply anaesthetized with sodium pentobarbital (100 mg/kg) administered intraperitoneally [19]. Successful anesthesia was confirmed by the absence of nocifensive movement, such as the tail flick reflex [16]. Hearts were then removed from the chest cavity and quickly mounted and perfused with normal Tyrode's (NT) solution to remove all blood.

Cardiac perfusion

In the HR experimental model, hearts were sequentially perfused with NT solution for 30 minutes and ischemic solution [20] for 30 minutes, followed by perfusion with NT solution with (non-treated) or without 10 μ M NecroX-5 (treated) for 60 minutes. In the control group, hearts were perfused with NT for 120 minutes.

Isolation of mitochondria

Mitochondrial pellets were collected as described previously [16,20,21]. Briefly, cardiac tissues were manually homogenized and the homogenate clarified by centrifugation at 1,000 g for 5 min at 4°C. The supernatant was collected and centrifuged at 10,000 g for 10 minutes, and mitochondrial pellets were collected.

RNA extraction and Real-time PCR

Total RNA was extracted using TRIZOL reagent (Invitrogen, CA, USA) according to the manufacturer's instructions. Frozen tissues (50–100 mg) were ground into powder in liquid nitrogen and then suspended in 1 mL TRIZOL Reagent. The aqueous phase was used for RNA precipitation using an equal volume of isopropanol. The RNA pellet was washed once with 1 mL 75% ethanol, then air-dried and re-dissolved in an appropriate volume of RNase-free water. RNA was quantified using a spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). cDNA was synthesized using Taqman RT reagents (Applied Biosystems, NY, USA), following the manufacturer's instructions. The cDNA synthesis thermal cycling program included the following steps: 65°C for 5 min, 4°C for 2 min, 37°C for 30 min, then 95°C for 5 min.

Relative mRNA expression levels of *Ndufv2*, *Idh3a*, *Ndufa1*, *Ndufb8*, *Idh1*, *Hyou1*, *Ak2*, *Lum*, *Cabc1* and *Nexn* genes were performed in triplicate using SYBR[®] Premix Ex Taq[™] II kit (Takara, Shiga, Japan) on CFX96. The mixture contains cDNA, SYBR green Taq polymerase mixture, and primers (Table 1). According to the manufacturer's guidelines, relative quantification was analyzed using the $\Delta\Delta$ CT method for. The mRNA level was normalized by control group.

Table 1. Primer list of the examined genes

| Gene ID | Full gene name | Forward primer | Reverse primer |
|---------|--|-----------------------|----------------------|
| NDUFV2 | NADH dehydrogenase flavoprotein 2, mitochondrial | tctctgcatgaacaagggtg | cgtttacacaggcccctaaa |
| IDH3A | Idh3a: Isocitrate dehydrogenase subunit alpha, mitochondrial | gcaggggaagttgcagagaac | accgattcaaagatggcaac |
| NDUFA1 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1 | acggtgaggagatgtggctc | caggccctggacacatagt |
| NDUFB8 | NADH dehydrogenase (Ubiquinone) 1 beta subcomplex 8 | gcttcatctgggcctgtaag | gctttgctctgtgggctaac |
| IDH1 | Isocitrate dehydrogenase cytoplasmic | gcttcatctgggcctgtaag | gctttgctctgtgggctaac |
| HYOU1 | hypoxia up-regulated 1 | aatcggcctaaaaccgtcct | aactttgggaacacgagtg |
| AK2 | Isoform 1 of Adenylate kinase 2, mitochondrial | agcaggctgaaatgcttgat | aagcggagtggtctgagtg |
| LUM | Lumican | tgcaaggctcattctgac | cctccttttgagctggtg |
| CABC1 | Chaperone activity of bc1 complex-like, mitochondrial | tctggaagccgaagttcagt | gagccttcattgactctgc |
| NEXN | Nexilin | aagaaaaccgcaagaagca | cagcaaatgctcttctcc |

Complex activity assay

The activity of mitochondrial complexes I, II, III, IV, and V were examined on mitochondria isolated from frozen heart tissue using a 96-well plate-based assay. The activities of complexes I, II, and IV were assessed using the corresponding Enzyme Activity Microplate Assay Kits (MitoSciences, Eugene, OR, USA) following manufacturer's instructions. A modified MitoTOX™ OXPHOS complex III activity kit (MitoSciences, Eugene, OR, USA) was used to quantify the activity of mitochondrial complex III. Data were presented as mOD/min or OD [22] and absorbance readings were obtained using a SpectraMax M2 microplate reader (Molecular Devices, Sunnyvale, CA, USA).

To measure mitochondrial complex I activity, a total of 20 µg of mitochondrial extract from each heart was used in a NADH oxidation assay. Mitochondrial complex I was immunocaptured within microplate wells. The reduction of redox dye and concurrent NADH oxidation to NAD⁺ indicated complex I activity and was observed as increased absorbance at 450 nm.

To measure mitochondrial complex II activity, a total of 5 mg/ml mitochondrial extract from each heart was used in a succinate-coenzyme Q reductase assay. Mitochondrial complex II was immunocaptured in wells coated with anti-Complex II monoclonal antibody. The production of ubiquinol coupled to the reduction of the dye 2, 6-dichlorophenolindophenol (DCPIP) indicated complex II activity and was observed as a decrease in absorbance at 600 nm.

To measure mitochondrial complex III activity, a total of 5 mg/ml mitochondrial extract from each heart was used, replacing the bovine heart mitochondria provided in the kit. The reduction of cytochrome c over time indicated mitochondrial complex III activity and was observed as a linear increase in absorbance at 550 nm. Rotenone and potassium cyanide were used to inhibit complex I and IV, respectively.

To measure mitochondrial complex IV activity, a total of 25 µg mitochondrial extract from each heart was immunocaptured within microplate wells. The oxidation of cytochrome c indicated mitochondrial complex IV activity and was observed as decreased absorbance at 550 nm.

Citrate synthase activity

The citrate synthase activity of mitochondrial extracts was measured using a citrate synthase assay kit (Sigma-Aldrich, St Louis, USA) per manufacturer's instructions. The reaction mixture contained 30 mM acetyl coenzyme A, 10 mM 5-dithiobis-2-nitrobenzoic acid, and 20–40 µg mitochondrial protein and was initiated with 10 mM oxaloacetic acid. Absorbance at 412 nm was monitored at 30-second intervals for 3 minutes at 25°C using a SpectraMax M2 microplate reader (Molecular Devices, Sunnyvale, CA, USA). Data are presented as units (µM/ml/min).

Protein extraction for LC-MS and peptide count protein quantification

Rat heart proteomes were analyzed by LC-MS and the non-labeled peptide count protein quantification method as described previously [23]. Briefly, dissolved heart proteins were separated on a 12% polyacrylamide gel by SDS-PAGE. Protein contained gels were sliced, dehydrated and swollen to elute the proteins for the tryptic peptide digestion. LC-MS/MS analysis was performed using a ThermoFinnigan ProteomeX workstation LTQ linear ion trap MS (Thermo Electron, San Jose, CA) equipped with NSI sources (Thermo Electron).

Protein annotation and functional network construction

Identified proteins were further categorized, annotated, and functional networks were constructed to understand the molecular functions and biological processes of each protein [24,25]. Systematic bioinformatics analysis of the HR and HR+necrox5 treated heart proteome was conducted using STRING 8.3 (Search Tool for the Retrieval of Interacting Genes/Proteins), Cytoscape and ClueGo.

Western blot

Protein extracts from myocardial tissues were homogenized

Table 2. Cardiac proteins with differential expression in HR and NecroX-5 post-hypoxic treated rat heart. MW (molecular weight) was obtained from the MASCOT data base

A. Down-regulated protein expression

| Identified Proteins | Identified Proteins | Accession Number | MW | Expression ratio (NecroX-5/HR) |
|---------------------|--|------------------|---------|--------------------------------|
| Vdac1 | Voltage-dependent anion-selective channel protein 1 | IPI00421874 | 31 kDa | 0.59 |
| Aifm1 | Apoptosis-inducing factor 1, mitochondrial | IPI00204118 | 67 kDa | 0.58 |
| LOC641316 | aldehyde dehydrogenase 4A1 | IPI00921682 | 62 kDa | 0.51 |
| Cpt1b | Carnitine O-palmitoyltransferase 1, muscle isoform | IPI00196647 | 88 kDa | 0.69 |
| Acad9 | Acad9 protein | IPI00337099 | 69 kDa | 0.65 |
| Prdx1 | Peroxiredoxin-1 | IPI00211779 | 22 kDa | 0.59 |
| Flnc s | Similar to Filamin-C isoform 2 | IPI00358175 | 291 kDa | 0.51 |
| Atp5j2 | Similar to ATP synthase, H+ transporting, mitochondrial F0 complex, isoform 2 | IPI00390086 | 10 kDa | 0.53 |
| Rrbp1 | similar to Ribosome-binding protein 1 | IPI00188079 | 144 kDa | 0.42 |
| Lamb1 | Lamb1 Protein | IPI00365542 | 203 kDa | 0.53 |
| Cat | Catalase | IPI00231742 | 60 kDa | 0.65 |
| Acads | Acetyl-Coenzyme A dehydrogenase, short chain | IPI00231359 | 45 kDa | 0.53 |
| Kpnb1 | Importin subunit beta-1 | IPI00204261 | 97 kDa | 0.55 |
| Vdac2 | Voltage-dependent anion-selective channel protein 2 | IPI00198327 | 32 kDa | 0.75 |
| Sptbn1 | Non-erythrocyte beta-spectrin | IPI00373419 | 251 kDa | 0.43 |
| Cdh13 | T-cadherin | IPI00200257 | 78 kDa | 0.45 |
| Atic | Bifunctional purine biosynthesis protein PURH | IPI00393333 | 64 kDa | 0.63 |
| Ech1 | Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial | IPI00326561 | 36 kDa | 0.41 |
| Ehd4 | Pincher | IPI00200271 | 61 kDa | 0.53 |
| Pdk1 | [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial | IPI00204957 | 49 kDa | 0.32 |
| Cep290 | 289 kDa protein | IPI00560237 | 289 kDa | 0.31 |
| Stip1 | Stress-induced-phosphoprotein 1 | IPI00213013 | 63 kDa | 0.41 |
| Prdx6 | Peroxiredoxin-6 | IPI00231260 | 25 kDa | 0.61 |
| Cct8 | Chaperonin containing Tcp1, subunit 8 | IPI00370815 | 60 kDa | 0.64 |
| Slc25a11 | Mitochondrial 2-oxoglutarate/malate carrier protein | IPI00231261 | 34 kDa | 0.42 |
| Me3 | mitochondrial malic enzyme 3 | IPI00870055 | 67 kDa | 0.37 |
| LOC682397 | LOC679594 similar to polyubiquitin | IPI00763565 | 9 kDa | 0.49 |
| Lum | Lumican | IPI00206403 | 38 kDa | 0.64 |
| Coq6 | Coenzyme Q6 homolog | IPI00471550 | 51 kDa | 0.63 |
| Tcp1 | T-complex protein 1 subunit alpha | IPI00200847 | 60 kDa | 0.61 |
| Rab10 | RAB10, member RAS oncogene family | IPI00555185 | 23 kDa | 0.27 |
| Aldh9a1 | 4-trimethylaminobutyraldehyde dehydrogenase | IPI00203690 | 56 kDa | 0.60 |
| Cox7c | Cytochrome c oxidase, subunit VIIc | IPI00564570 | 7 kDa | 0.58 |
| Clpp | Putative ATP-dependent Clp protease proteolytic subunit, mitochondrial precursor | IPI00373718 | 30 kDa | 0.58 |
| Nexn | Nexilin | IPI00209938 | 78 kDa | 0.75 |

B. Up-regulated protein expression

| Identified Proteins | Identified Proteins | Accession Number | MW | Expression ratio (NecroX-5/HR) |
|---------------------|--|------------------|---------|--------------------------------|
| Atp5i | ATP synthase subunit e, mitochondrial | IPI00231978 | 8 kDa | 1.46 |
| Ak1 | Adenylate kinase isoenzyme 1 | IPI00210351 | 22 kDa | 1.65 |
| Ndufv1 | NADH dehydrogenase (Ubiquinone) flavoprotein 1 | IPI00191913 | 51 kDa | 1.28 |
| Idh3a | Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial | IPI00198720 | 40 kDa | 2.26 |
| Pccb | Propionyl coenzyme A carboxylase, beta polypeptide | IPI00851115 | 59 kDa | 1.93 |
| Krt2 | 69 kDa protein | IPI00551558 | 69 kDa | 1.63 |
| Col1a2 | Collagen alpha-2(I) chain | IPI00188921 | 130 kDa | 3.85 |
| Atp5l | ATP synthase, H+ transporting, mitochondrial F0 complex, subunit G | IPI00421711 | 11 kDa | 1.19 |
| Ndufv2 | NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial | IPI00367152 | 27 kDa | 2.02 |
| Hbb | Hemoglobin subunit beta-1 | IPI00230897 | 16 kDa | 1.83 |
| LOC360504 | hemoglobin alpha 2 chain | IPI00205036 | 15 kDa | 2.07 |

Table 2. Continued

| Identified Proteins | Identified Proteins | Accession Number | MW | Expression ratio (NecroX-5/HR) |
|---------------------|--|------------------|---------|--------------------------------|
| Gpx1 | Glutathione peroxidase 1 | IPI00192301 | 22 kDa | 1.82 |
| Jup | Junction plakoglobin | IPI00421429 | 82 kDa | 1.78 |
| Bag3 | Bcl-2-interacting death suppressor | IPI00203974 | 62 kDa | 1.21 |
| Krt83 | LOC681126 protein | IPI00858382 | 55 kDa | 3.17 |
| Dcn | Decorin | IPI00199861 | 40 kDa | 3.5 |
| Ndufs4 | NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial | IPI00212052 | 20 kDa | 1.26 |
| Rab11b | Ras-related protein Rab-11B | IPI00210381 | 24 kDa | 2.30 |
| Ak3 | GTP:AMP phosphotransferase mitochondrial | IPI00362243 | 25 kDa | 1.36 |
| Atp5e | ATP synthase subunit epsilon, mitochondrial | IPI00231411 | 6 kDa | 1.5 |
| Ndufs2 | NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial | IPI00471647 | 53 kDa | 1.59 |
| Selenbp1 | Selenium-binding protein 1 | IPI00208026 | 53 kDa | 1.74 |
| Ndufa5 | NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 | IPI00231997 | 13 kDa | 1.36 |
| Krt31 | Type I hair keratin KA25 | IPI00193750 | 47 kDa | 2.26 |
| Ndufb8 | NADH dehydrogenase (Ubiquinone) 1 beta subcomplex 8 (Predicted), isoform CRA_a | IPI00370372 | 22 kDa | 3.61 |
| Smc6l1 | SMC6 structural maintenance of chromosomes 6-like 1 | IPI00360352 | 127 kDa | 2.19 |
| Plec1 | Plectin 6 | IPI00209000 | 534 kDa | 1.9 |
| Uba1 | Ubiquitin-like modifier-activating enzyme 1 | IPI00368347 | 118 kDa | 2.16 |
| Cabc1 | Chaperone activity of bc1 complex-like, mitochondrial | IPI00555310 | 72 kDa | 1.06 |
| Myh9 | Myosin-9 | IPI00209113 | 226 kDa | 1.86 |
| Krt86 | Type II keratin Kb26 | IPI00454477 | 57 kDa | 3.35 |
| Ak2 | Isoform 1 of Adenylate kinase 2, mitochondrial | IPI00230857 | 26 kDa | 1.24 |
| Cltc | Clathrin heavy chain 1 | IPI00193983 | 192 kDa | 1.87 |
| Cox5b | Cytochrome c oxidase subunit 5B, mitochondrial | IPI00193918 | 14 kDa | 1.34 |
| Hspa4 | Heat shock 70 kDa protein 4 | IPI00387868 | 94 kDa | 2.13 |
| Hmgb1-ps3 | Similar to High mobility group protein 1 | IPI00366734 | 24 kDa | 2.02 |
| Krt85 | Type II keratin Kb25 | IPI00200792 | 56 kDa | 7.17 |
| Hyou1 | hypoxia up-regulated 1 | IPI00655289 | 111 kDa | 2.47 |
| Wdr1 | WD repeat-containing protein 1 | IPI00215349 | 66 kDa | 1.92 |
| Phpt1 | Phosphohistidine phosphatase 1 | IPI00212258 | 14 kDa | 2.00 |
| LOC684828 | Similar to Histone H1.2 | IPI00766273 | 22 kDa | |
| Dnah9 | Similar to dynein, axonemal, heavy polypeptide 9 isoform 2 | IPI00205973 | 512 kDa | 1.91 |
| Hibadh | 3-hydroxyisobutyrate dehydrogenase, mitochondrial | IPI00202658 | 35 kDa | 2.07 |
| Ndufa1 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1 | IPI00769025 | 14 kDa | 1.68 |
| Timm13 | Mitochondrial import inner membrane translocase subunit Tim13 | IPI00212651 | 10 kDa | 1.73 |
| Fgb | Isoform 1 of Fibrinogen beta chain | IPI00205389 | 54 kDa | 2.06 |
| Krt84 | Type II keratin Kb24 | IPI00421784 | 61 kDa | 4.65 |
| Idh1 | Isocitrate dehydrogenase [NADP] cytoplasmic | IPI00194045 | 47 kDa | 3.42 |

in ice-cold Radioimmunoprecipitation assay (RIPA) buffer containing 25 mM/L Tris · HCl (pH 7.6), 150 mM/L NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, a protease inhibitor cocktail, and a phosphatase inhibitor cocktail. After brief sonication, the homogenized sample was centrifuged at 13,500 g for 30 minutes at 4°C. Protein concentration was determined using a bicinchoninic acid assay (BCA) assay kit (Pierce, Rockford, IL, USA).

Briefly, 50~100 µg of protein from each heart was separated by 10~12% SDS-PAGE, transferred onto nitrocellulose membranes (GE Healthcare, Chalfont St. Giles, UK), and blocked for 2 hours in 5% skim milk (pH 7.6) at room temperature. Membranes

were then probed overnight at 4°C with rabbit polyclonal anti-PGC1α antibody (Abcam, Cambridge, UK) or mouse monoclonal α-tubulin antibody (Sigma-Aldrich, St Louis, USA) diluted 1:1000. Membranes were then washed three times with phosphate-buffered saline containing Tween 20 (PBS-T; pH 7.4) and incubated for two hours at room temperature with anti-rabbit or anti-mouse IgG horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1:2000 dilution. After three more washes with PBS-T, membrane-bound proteins were visualized using a western blot detection kit (AbClon Inc., Seoul, Korea). ImageJ software, National Institutes of Health, Washington, USA was

used to quantify protein bands. Experiments were performed in triplicate.

Statistical analyses

Data are presented as the mean \pm standard error of the mean (SEM). Using Origin 8.0 software (Origin Lab, Northampton, MA, USA), the differences between control and treatment groups were evaluated by one-way analysis of variance (ANOVA) and the control to treatment comparison over time was tested using a two-way ANOVA. p -values ≤ 0.05 were considered significant.

RESULTS

Alterations in protein levels in HR and NecroX-5 treatment groups

We used LC-MS to conduct protein expression profiling of

Necro-X5 treated, non-treated, and control hearts. The expression levels of several identified proteins in hearts experiencing HR and NecroX-5-treated hearts are listed in Table 2. Cardiac proteins with differential expression levels among groups were classified based on their molecular functions (Fig. 1A, B) and a protein-protein interaction network was constructed. Using Clusters of Orthologous Groups of Proteins (COGs) (Fig. 1C), the proteins were divided into the following functional groups: 1) cell cycle control, cell division, chromosome partitioning; 2) lipid transport and metabolism; 3) amino acid transport and metabolism; 4) defense mechanism; 5) RNA processing and modification; 6) nucleotide transport and metabolism; 7) extracellular structures; 8) energy production and conversion; 9) posttranslational modification, protein turnover, chaperones; 10) cytoskeleton; 11) signal transduction mechanism; and 12) general function prediction only.

Of these proteins, 35 were down-regulated proteins involving in hydrogen peroxide catabolic process, fatty acid oxidation, carnitine metabolic process, aerobic respiration, the




Fig. 1. Functional groups and protein-protein interactions of proteins identified in control, HR, and NecroX-5 treated rat hearts. (A) A Venn diagram illustrates all possible logical relationships between proteins identified in control, HR, and NecroX-5 treated rat hearts. (B) A protein-protein interaction network built on identified proteins illustrates their proposed interactions in various cellular processes. (C) Functional protein groups were determined by interactive merging of initially defined groups based on the number or percentage of genes provided per term. (D) Identified proteins are presented based on their molecular functions in up- and down-regulated biological processes (Bonferonni corrected p -values).

DNA catabolic process, and endonucleolytic and *de novo* post-translational protein folding (Table 2A and Fig. 1D). Interestingly, 48 up-regulated proteins were involved in a number of key pathways, including cellular respiration, the ATP metabolic process, the hydrogen peroxide catabolic process, and nucleobase-containing small molecule interconversion. Specifically, the expression of complex I (Ndufv2, Ndufa5, Ndufb8), complex II (Idh3a), and complex V (Atp5i, Atp5l) proteins, which are involved in the OXPHOS system and metabolic modulation, was increased in hearts tissue treated with NecroX-5 (Table 2).

mRNA and protein expression levels and HR and NecroX-5 treated hearts reveals a NecroX-5-mediated protective effect

Ten genes coding for up-regulated proteins (such as, Ndufv2, Ndufa1, Ndufb8, Idh3a, Idh1, Hyou1, Ak2, Cabc1) and down-regulated proteins (Lum, Nexn) were randomly subjected to real-time PCR to confirm LC-MS data. As shown in Fig. 2, relative protein expression levels (NecroX-5 vs. HR hearts) corresponded quite well with relative mRNA expression levels.

We assumed that mitochondrial changes might be associated with alterations in mitochondrial biogenesis. To evaluate our hypothesized pathway, we determined mRNA and protein expression levels of PGC1 α , a mitochondrial biogenesis regulator candidate, via western blot (Fig. 3). NecroX-5 treatment of rat hearts significantly attenuated HR-induced reduced PGC1 α mRNA expression levels (Fig. 3A). Consistent with real-time-PCR data, PGC1 α protein expression levels were markedly higher in NecroX-5 treated hearts compared to those from HR hearts (Fig. 3B).

Mitochondrial parameters

We then further examined the protective effects of NecroX-5 on HR injury in the context of mitochondrial energy metabolism.





Fig. 2. Quantitative real-time-PCR validation of LC-MS-mediated protein identification. A histogram shows the ratio of summarized representative protein and mRNA expression levels between HR and NecroX-5 treated hearts. $n=3\sim5$ for each group, $^{\dagger}p<0.05$. Ndufv2: NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial; Idh3a: Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial; Ndufa1: NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1; Ndufb8: NADH dehydrogenase (Ubiquinone) 1 beta subcomplex 8; Idh1: Isocitrate dehydrogenase [NADP] cytoplasmic; Hyou1: hypoxia up-regulated 1; Ak2: Isoform 1 of Adenylate kinase 2, mitochondrial; Lum: Lumican; Cabc1: Chaperone activity of bc1 complex-like, mitochondrial; Nexn: Nexilin.

A,



B,




Fig. 3. PGC1 α mRNA and protein expression levels in control, HR, and NecroX-5 treated hearts. Real-time PCR and Western blot were performed to assess mRNA expression (A) and protein expression (B) of PGC1 α normalized to α -tubulin in rat hearts. Cardiac tissue was selected from untreated HR hearts and HR hearts treated with 10 μ M NecroX-5. $n=3\sim6$ for each group; $*p<0.05$ vs. control, $^{\dagger}p<0.05$ vs. HR.




Fig. 4. Mitochondrial complex and citrate synthase activities in HR and NecroX-5 treated hearts. Graphs illustrated the activity of mitochondrial complexes I~V (mOD/min) with the relative Vmax curves of complex I~V activity (OD) (A~E, upper panels) and mitochondrial citrate synthase activity (F) in untreated HR hearts and NecroX-5 treated HR hearts. n=4~5 for each group; *p<0.05.

Mitochondrial complex activities were tested after 60 minutes of reperfusion. The activities of complex I, II, and V (mOD/min) were significantly higher in NecroX-5 treated hearts (37.44 ± 1.59 , 3.74 ± 0.18 , and 1.41 ± 0.09 , respectively; $p < 0.05$) compared to HR (non-treated) hearts (33.33 ± 1.09 , 3.30 ± 0.26 , and 1.23 ± 0.10 , respectively). However, there was no significant difference in the complex III activity (17.82 ± 5.98 and 23.67 ± 2.29), complex IV activity (7.49 ± 1.69 and 7.61 ± 0.90 , respectively), or citrate synthase activity (2.58 ± 0.91 and 2.36 ± 1.08 units) between HR group and NecroX-5 group (Fig. 4).

DISCUSSION

Here, we show that NecroX-5 significantly improves mitochondrial function in rat hearts experiencing HR injury by preserving mitochondrial oxidative phosphorylation capacity and PGC1 α expression.

NecroX-5 protects mitochondrial function against HR

Previous studies have clearly indicated that NecroX-5 suppresses OXPHOS system dysfunction and the tricarboxylic

acid cycle in rat hearts undergoing HR [16]. Improved oxygen consumption indexes and maintenance of the $\Delta\psi_m$ further support the protective effects of NecroX-5 on mitochondrial metabolism in hypoxic cardiac tissue [16]. The assessment of mitochondrial complex activity is a common approach for characterizing mitochondrial bioenergetics dysfunction, with higher expression levels of mitochondrial complex proteins corresponding to increased mitochondrial complex activity. Given this, mitochondrial complex activities and protein expression levels which are involved in the OXPHOS system and metabolic modulation were increased in NecroX-5 received hearts compared to those in HR hearts (Fig. 4, Table 2).

Any decrease in OXPHOS protein levels could adversely affect the $\Delta\psi_m$, further contributing to mitochondrial malfunction. Mitochondrial complex I is well-known to play an important role in maintaining the $\Delta\psi_m$ [26], and mitochondrial complex I deficiency is responsible for 40% of OXPHOS disorders [27]. As a core subunit of this complex, Ndufv2 is a key regulator of complex I activity; depletion of this protein causes a decrease in complex I activity. Mutation of the Ndufv2 gene causes cardiomyopathy [28]. In addition to preserving mitochondrial complex I and II protein levels and activities, NecroX-5 also significantly suppressed the HR-induced defects in mitochondrial complex V (the ATP

synthase complex). These results together with our earlier study [16] suggest that mitochondrial ATP generating capacity is improved in HR hearts upon NecroX-5 treatment. Additionally, a high rate of respiration control in NecroX-5 treated hearts may result from a properly functioning OXPHOS pathway, suggesting that the mitochondria have a high capacity for substrate oxidation and ATP turnover [6]. These observations suggest that treated hearts undergoing HR with NecroX-5 prevents the loss of crucial OXPHOS subunit proteins and, therefore, suppresses mitochondrial malfunction. As described in Table 2, the expression levels of other proteins involved in energetic metabolism, such as Idh1 and Idh3a (glycolysis) were higher in NecroX-5-treated hearts [21]. All of these processes would provide sufficient energy for ATP metabolism (see up-regulated biological process, Fig. 1D and Table 2B), leading to improved cardiac performance [16].

One research group previously demonstrated that malfunction of mitochondrial bioenergetics is coupled with complex II deficiency-mediated calcium handling [29]. In this, mitochondrial complex II protein expression activity were higher in NecroX-5 hearts, further supporting the previously described inhibitory role of NecroX-5 on the mitochondrial calcium uniporter [16]. Additionally, we previously described lower reactive oxygen species (ROS) production in NecroX-5 treated hearts compared to HR hearts [16]. Therefore, the improvement of complex II activity upon NecroX-5 treatment may contribute to improved modulation of ROS production in mitochondrial complexes I and III during HR injury [30].

Decreased PGC1 α levels have been observed in myocardial infarcted rat hearts; however, treatment of metformin [14] or losartan [13] can improve left ventricular function with significantly higher PGC1 α expression levels. Levels also increased within 3 hours after short-term deprivation of nutrients and oxygen conditions such as in IR and HR [31-33]. Although PGC1 α expression increased after a longer period of oxygen deprivation, acute HR or IR is associated with PGC1 α levels [32,33]. It has been shown that transcriptional suppression of autophagy-lysosome proteins and reduced activation of transcription factor EB (TFEB) are essential for sustaining lysosome function and enhancing cell survival under starvation conditions [34]. Upregulation of beclin-1 upon of HR-associated ROS elevation suppressed the TEEB-PGC1 α axis, triggering IR-induced cardiomyocyte death [33]. We also tested whether changes in mitochondrial function were associated with alterations in mitochondrial biogenesis by evaluating the expression of PGC1 α , a mitochondrial biogenesis regulator candidate. Consistent with previous reports [13,14,32,33], PGC1 α mRNA and protein levels were significantly higher in NecroX-5 treated hearts compared to untreated HR hearts. Additionally, ROS and Ca²⁺ can increase PGC1 α degradation [35]; therefore, increased PGC1 α levels in NecroX-5 group may be a result of lower ROS and calcium levels, as shown in our previous study [16]. We suggest that NecroX-5

treatment induces mitochondrial biogenesis regulatory programs to augment cardiac tolerance to hypoxic injury by preserving the capacity of the OXPHOS pathway to maintain mitochondrial energetics and modulate ROS in response to metabolic stress [10,16].

The beneficial effects of NecroX-5 on mitochondrial function may be achieved by several mechanisms. First, NecroX-5 could prevent the reduction of OXPHOS proteins and increase OXPHOS maximal capacity in HR hearts. Second, preserved OXPHOS capacity by NecroX-5 can produce ATP more effectively than is seen in HR hearts during the early reoxygenation period. Additionally, increased biogenesis is likely to be associated with improved mitochondrial bioenergetics (Fig. 4 and 5). Therefore, augmented bioenergetics upon NecroX-5 treatment may aid in mitochondrial resistance to ischemic injury [10]. Combined with our previous report [16], the proposed function of NecroX-5 described here (Fig. 5) suggests for the first time that the protection of OXPHOS capacity and preservation of PGC1 α expression may account for the protective effects of NecroX-5 against HR-induced injury. However, our present data were based on *in vitro* and *ex vivo* models. Therefore, *in vivo* testing is necessary for a more thorough understanding of the role of NecroX-5 during HR-induced injury. Additionally, based




Fig. 5. Proposed function of NecroX-5 during HR injury. ETC, electron transport chain; HR, hypoxia/reoxygenation.

on proteomics data (unpublished data); further studies should be done to address more comprehensive roles and mechanical actions of NecroX-5 in the context of HR-induced injury.

ACKNOWLEDGEMENTS

This work was supported by the National Research Foundation of Korea (NRF). Funds were granted by the Ministry of Science, ICT, and Future Planning of Korea (2012R1A2A1A03007595) and by the Ministry of Education of Korea (2010-0020224).

REFERENCES

1. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. *J Pathol*. 2000;190:255-266.
2. Halestrap AP. A pore way to die: the role of mitochondria in reperfusion injury and cardioprotection. *Biochem Soc Trans*. 2010;38:841-860.
3. Kleinbongard P, Schulz R, Heusch G. TNF α in myocardial ischemia/reperfusion, remodeling and heart failure. *Heart Fail Rev*. 2011;16:49-69.
4. Ribichini F, Wijns W. Acute myocardial infarction: reperfusion treatment. *Heart*. 2002;88:298-305.
5. Xia A, Xue Z, Wang W, Zhang T, Wei T, Sha X, Ding Y, Zhou W. Naloxone postconditioning alleviates rat myocardial ischemia reperfusion injury by inhibiting JNK activity. *Korean J Physiol Pharmacol*. 2014;18:67-72.
6. Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. *Biochem J*. 2011;435:297-312.
7. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. *Physiol Rev*. 2008;88:581-609.
8. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, André-Fouët X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. *N Engl J Med*. 2008;359:473-481.
9. Heller A, Brockhoff G, Goepferich A. Targeting drugs to mitochondria. *Eur J Pharm Biopharm*. 2012;82:1-18.
10. McLeod CJ, Pagel I, Sack MN. The mitochondrial biogenesis regulatory program in cardiac adaptation to ischemia--a putative target for therapeutic intervention. *Trends Cardiovasc Med*. 2005;15:118-123.
11. Kim HK, Thu VT, Heo HJ, Kim N, Han J. Cardiac proteomic responses to ischemia-reperfusion injury and ischemic preconditioning. *Expert Rev Proteomics*. 2011;8:241-261.
12. Ventura-Clapier R, Garnier A, Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1 α . *Cardiovasc Res*. 2008;79:208-217.
13. Sun CK, Chang LT, Sheu JJ, Wang CY, Youssef AA, Wu CJ, Chua S, Yip HK. Losartan preserves integrity of cardiac gap junctions and PGC-1 α gene expression and prevents cellular apoptosis in remote area of left ventricular myocardium following acute myocardial infarction. *Int Heart J*. 2007;48:533-546.
14. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A, Anaya-Cisneros M, Tian R, Lefler DJ. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. *Circ Res*. 2009;104:403-411.
15. Kim HJ, Koo SY, Ahn BH, Park O, Park DH, Seo DO, Won JH, Yim HJ, Kwak HS, Park HS, Chung CW, Oh YL, Kim SH. NecroX as a novel class of mitochondrial reactive oxygen species and ONOO⁻ scavenger. *Arch Pharm Res*. 2010;33:1813-1823.
16. Thu VT, Kim HK, Long le T, Lee SR, Hanh TM, Ko TH, Heo HJ, Kim N, Kim SH, Ko KS, Rhee BD, Han J. NecroX-5 prevents hypoxia/reoxygenation injury by inhibiting the mitochondrial calcium uniporter. *Cardiovasc Res*. 2012;94:342-350.
17. Lee SR, Lee SJ, Kim SH, Ko KS, Rhee BD, Xu Z, Kim N, Han J. NecroX-5 suppresses sodium nitroprusside-induced cardiac cell death through inhibition of JNK and caspase-3 activation. *Cell Biol Int*. 2014;38:702-707.
18. Choi JM, Park KM, Kim SH, Hwang DW, Chon SH, Lee JH, Lee SY, Lee YJ. Effect of necrosis modulator necrox-7 on hepatic ischemia-reperfusion injury in beagle dogs. *Transplant Proc*. 2010;42:3414-3421.
19. Takaseya T, Ishimatsu M, Tayama E, Nishi A, Akasu T, Aoyagi S. Mechanical unloading improves intracellular Ca²⁺ regulation in rats with doxorubicin-induced cardiomyopathy. *J Am Coll Cardiol*. 2004;44:2239-2246.
20. Kim N, Lee Y, Kim H, Joo H, Youm JB, Park WS, Warda M, Cuong DV, Han J. Potential biomarkers for ischemic heart damage identified in mitochondrial proteins by comparative proteomics. *Proteomics*. 2006;6:1237-1249.
21. Thu VT, Kim HK, Ha SH, Yoo JY, Park WS, Kim N, Oh GT, Han J. Glutathione peroxidase 1 protects mitochondria against hypoxia/reoxygenation damage in mouse hearts. *Pflugers Arch*. 2010;460:55-68.
22. Kim HK, Song IS, Lee SY, Jeong SH, Lee SR, Heo HJ, Thu VT, Kim N, Ko KS, Rhee BD, Jeong DH, Kim YN, Han J. B7-H4 downregulation induces mitochondrial dysfunction and enhances doxorubicin sensitivity via the cAMP/CREB/PGC1- α signaling pathway in HeLa cells. *Pflugers Arch*. 2014;466:2323-2338.
23. Kim HK, Kim YK, Song IS, Lee SR, Jeong SH, Kim MH, Seo DY, Kim N, Rhee BD, Ko KS, Tark KC, Park CG, Cho JY, Han J. Human giant congenital melanocytic nevus exhibits potential proteomic alterations leading to melanotumorigenesis. *Proteome Sci*. 2012;10:50.
24. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pagès F, Trajanoski Z, Galon J. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics*. 2009;25:1091-1093.
25. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M, Bork P, von Mering C. STRING 8--a global view on proteins and their functional interactions in 630 organisms. *Nucleic Acids Res*. 2009;37:D412-D416.
26. Distelmaier F, Koopman WJ, van den Heuvel LP, Rodenburg RJ, Mayatepek E, Willems PH, Smeitink JA. Mitochondrial complex I deficiency: from organelle dysfunction to clinical disease. *Brain*. 2009;132:833-842.

27. Morán M, Rivera H, Sánchez-Aragó M, Blázquez A, Merinero B, Ugalde C, Arenas J, Cuezva JM, Martín MA. Mitochondrial bioenergetics and dynamics interplay in complex I-deficient fibroblasts. *Biochim Biophys Acta*. 2010;1802:443-453.
28. Bénit P, Beugnot R, Chretien D, Giurgea I, De Lonlay-Debeney P, Issartel JP, Corral-Debrinski M, Kerscher S, Rustin P, Rötig A, Munnich A. Mutant NDUFB2 subunit of mitochondrial complex I causes early onset hypertrophic cardiomyopathy and encephalopathy. *Hum Mutat*. 2003;21:582-586.
29. Mbaya E, Oulès B, Caspersen C, Tacine R, Massinet H, Pennuto M, Chrétien D, Munnich A, Rötig A, Rizzuto R, Rutter GA, Paterlini-Bréchet P, Chami M. Calcium signalling-dependent mitochondrial dysfunction and bioenergetics regulation in respiratory chain Complex II deficiency. *Cell Death Differ*. 2010;17:1855-1866.
30. Gill RS, Lee TF, Manouchehri N, Liu JQ, Lopaschuk G, Bigam DL, Cheung PY. Postresuscitation cyclosporine treatment attenuates myocardial and cardiac mitochondrial injury in newborn piglets with asphyxia-reoxygenation. *Crit Care Med*. 2013;41:1069-1074.
31. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, Cooper M, Laznik D, Chinsomboon J, Rangwala SM, Baek KH, Rosenzweig A, Spiegelman BM. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. *Nature*. 2008;451:1008-1012.
32. Ma X, Liu H, Foyil SR, Godar RJ, Weinheimer CJ, Hill JA, Diwan A. Impaired autophagosome clearance contributes to cardiomyocyte death in ischemia/reperfusion injury. *Circulation*. 2012;125:3170-3181.
33. Ma X, Liu H, Murphy JT, Foyil SR, Godar RJ, Abuirqeba H, Weinheimer CJ, Barger PM, Diwan A. Regulation of the transcription factor EB-PGC1alpha axis by beclin-1 controls mitochondrial quality and cardiomyocyte death under stress. *Mol Cell Biol*. 2015;35:956-976.
34. Settembre C, De Cegli R, Mansueto G, Saha PK, Vetrini F, Visvikis O, Huynh T, Carissimo A, Palmer D, Klisch TJ, Wollenberg AC, Di Bernardo D, Chan L, Irazoqui JE, Ballabio A. TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. *Nat Cell Biol*. 2013;15:647-658.
35. Rasbach KA, Green PT, Schnellmann RG. Oxidants and Ca²⁺ induce PGC-1alpha degradation through calpain. *Arch Biochem Biophys*. 2008;478:130-135.